Paper36975206
Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.
Ressing M and 11 others. Cancer Rep (Hoboken), 2023. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors. Papers, record 36975206. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36975206
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Drug Dosage Calculations | Major topic |
| Humans | |
| Child | |
| Neoplasms | |
| Algorithms |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12788587 | Adrenal insufficiency. | Lancet | 2003 | https://conductscience.org/library/papers/12788587 | PubMed |
| 2 | 10789823 | Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. | Drug Saf | 2000 | https://conductscience.org/library/papers/10789823 | PubMed |
| 3 | 22124095 | Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22124095 | PubMed |
| 4 | 12637473 | Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. | J Clin Oncol | 2003 | https://conductscience.org/library/papers/12637473 | PubMed |
| 5 | 16965909 | Role of radiotherapy and chemotherapy in the risk of secondary leukaemia after a solid tumour in childhood. | Eur J Cancer | 2006 | https://conductscience.org/library/papers/16965909 | PubMed |
| 6 | 8334677 | Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. | Cancer Treat Rev | 1993 | https://conductscience.org/library/papers/8334677 | PubMed |
| 7 | 16895963 | The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. | J Clin Endocrinol Metab | 2006 | https://conductscience.org/library/papers/16895963 | PubMed |
| 8 | 2737789 | Doxorubicin and epirubicin cardiotoxicity: experimental and clinical aspects. | Int J Clin Pharmacol Ther Toxicol | 1989 | https://conductscience.org/library/papers/2737789 | PubMed |
| 9 | 10492065 | A critical risk-benefit assessment argues against the use of anthracyclines in induction regimens for newly diagnosed childhood acute lymphoblastic leukemia. | Leuk Lymphoma | 1999 | https://conductscience.org/library/papers/10492065 | PubMed |
| 10 | 2194535 | New cytotoxic drugs in treatment of breast cancer. | Acta Oncol | 1990 | https://conductscience.org/library/papers/2194535 | PubMed |
| 11 | 10710274 | Persistent hypokalemia after successful adrenalectomy in a patient with Cushing's syndrome due to ectopic ACTH secretion: possible role of 11beta-hydroxysteroid dehydrogenase inhibition. | J Endocrinol Invest | 1999 | https://conductscience.org/library/papers/10710274 | PubMed |
| 12 | 2015395 | Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. | Blood | 1991 | https://conductscience.org/library/papers/2015395 | PubMed |
| 13 | 1723369 | Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. | Drugs | 1991 | https://conductscience.org/library/papers/1723369 | PubMed |
| 14 | 8329832 | Temporal and individual variations in the dose of glucocorticoid used for the treatment of salt-losing congenital virilizing adrenal hyperplasia due to 21-hydroxylase deficiency. | Acta Paediatr Suppl | 1993 | https://conductscience.org/library/papers/8329832 | PubMed |
| 15 | 9792296 | A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group. | Br J Haematol | 1998 | https://conductscience.org/library/papers/9792296 | PubMed |
| 16 | 26747086 | Cardiac Outcomes in Adult Survivors of Childhood Cancer Exposed to Cardiotoxic Therapy: A Cross-sectional Study. | Ann Intern Med | 2016 | https://conductscience.org/library/papers/26747086 | PubMed |
| 17 | 39976936 | The Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review. | JAMA Oncol | 2025 | https://conductscience.org/library/papers/39976936 | PubMed |
| 18 | 26304888 | Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26304888 | PubMed |
| 19 | 32779106 | What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study. | J Endocrinol Invest | 2021 | https://conductscience.org/library/papers/32779106 | PubMed |
| 20 | 12531809 | Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. | Blood | 2003 | https://conductscience.org/library/papers/12531809 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37530985 | Subsequent primary neoplasms after childhood cancer therapy - design and description of the German nested case-control study STATT-SCAR. | Cancer Causes Control | 2024 | https://conductscience.org/library/papers/37530985 | PubMed |
| 36975206 | Equivalent doses for anticancer agents used in pediatric oncology: A literature review and evaluation of a novel approach for conversion factors. | Cancer Rep (Hoboken) | 2023 | https://conductscience.org/library/papers/36975206 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36975206
GET https://conductscience.org/api/papers/v1/36975206/references?page=2